MAZE
NASDAQMaze Therapeutics Inc.
News25/Ratings7
News · 26 weeks65+1100%
2026-03-012026-08-23
Mix2990d
- Insider20(69%)
- SEC Filings7(24%)
- Other2(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Kornowski Sophie4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson Paula A4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kornowski Sophie3 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 3 filed by new insider Johnson Paula A3 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECMaze Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- INSIDERPresident, R&D & CMO Bernstein Harold exercised 16,142 shares at a strike of $10.42 and sold $445,621 worth of shares (16,142 units at $27.61) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- PRMaze Therapeutics Announces Appointments to Its Board of DirectorsPaula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. "We are excited to welcome Paula and Sophie to our Board at this important time for our company. With key progress made in our development programs, we
- SECSEC Form 10-Q filed by Maze Therapeutics Inc.10-Q - Maze Therapeutics, Inc. (0001842295) (Filer)
- SECMaze Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- PRMaze Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsEnrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the second q
- INSIDERChief Executive Officer Coloma Jason V sold $922,315 worth of shares (34,501 units at $26.73) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- INSIDERCSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $205,031 worth of shares (7,500 units at $27.34) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERPresident, R&D & CMO Bernstein Harold exercised 14,609 shares at a strike of $10.42 and sold $436,864 worth of shares (14,609 units at $29.90) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERChief Executive Officer Coloma Jason V sold $1,034,253 worth of shares (34,501 units at $29.98) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERCSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $210,150 worth of shares (7,500 units at $28.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- INSIDERChief Executive Officer Coloma Jason V sold $725,495 worth of shares (27,858 units at $26.04) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Spiegelman Daniel K4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Scheller Richard H4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Lim Jonathan E4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoppenot Herve4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Homcy Charles J4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Andrews Nancy C4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 8-K filed by Maze Therapeutics Inc.8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
MAZE FAQ
6 questionsWhere does MAZE stock trade?
Maze Therapeutics Inc. (MAZE) is listed on NASDAQ.What sector and industry is MAZE in?
Maze Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Maze Therapeutics Inc. go public?
Maze Therapeutics Inc. (MAZE) completed its IPO in 2025.What are analysts saying about MAZE?
Maze Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-03-18. Recent price targets range from $1700.00 to $3400.00.What companies are similar to MAZE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare MAZE side-by-side with any of them on Quantisnow.How can I track MAZE on Quantisnow?
Quantisnow aggregates Maze Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MAZE to receive live email and push alerts on every new disclosure.